RYRui Yang

Rui Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rui Yang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Fenglei Yu

    Department of Thoracic Surgery, the Second Xiangya Hospital, Central South University, Changsha, China

    2 shared publications
  • Xiang Wang

    Department of Thoracic Surgery, the Second Xiangya Hospital, Central South University, Changsha, China

    2 shared publications
  • Yongguang Tao

    Department of Pathology, Xiangya Hospital, Central South University, Changsha, China

    2 shared publications
  • Boxue He

    Department of Thoracic Surgery, the Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan, China

    1 shared publication
  • Chao Mao

    Department of Pathology, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Xiangya Hospital, Central South University, Changsha, 410078, Hunan, China

    1 shared publication
  • Christopher Wang

    Department of Thoracic Surgery, the Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan, China; Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, the Second Xiangya Hospital of Central South University, 410011, Changsha, Hunan, China

    1 shared publication

Latest Publications

  • The YTHDF3-DT/miR-301a-3p /INHBA axis attenuates autophagy-dependent ferroptosis in lung adenocarcinoma

    by Xiong Peng, Rui Yang, Christopher Wang, Weilin Peng, Zhenyu Zhao, Shuai Shi, Qidong Cai, Boxue He, Li Wang, Fenglei Yu, et al.


  • Open Access

    LSH interacts with and stabilizes GINS4 transcript that promotes tumourigenesis in non-small cell lung cancer

    by Rui Yang, Na Liu, Ling Chen, Yiqun Jiang, Ying Shi, Chao Mao, Yating Liu, Min Wang, Weiwei Lai, Haosheng Tang, et al.

    Elucidating mechanisms in oncogenes and epigenetic modifiers are needed to gain insights into the etiology and treatment of cancer, regulation of oncogene by chromatin modifiers at post-transcriptional level is critical and remains unclear. We have investigated the role of GINS4 in NSCLC. The expression of chromatin modifier lymphoid-specific helicase (LSH) and GINS4 was assessed in tumor and normal tissue from 79 patients with NSCLC with clinical characteristics. HBE, A549, H358, and H522, PC9, 95C and 95D were cultured after overexpression or silencing of GIAT4RA. Cell proliferation assay, cell migration and invasion assays, plate colony formation assay, immunofluorescence assay, Operetta® high-content screening and analysis, Western blot analysis and Co-Immunoprecipitation (Co-IP) assay, RNA immunoprecipitation assay and tumor growth assay was used to address the potential interplay of between GINS4 and LSH, and the functional of GINS4. GINS4 is highly expressed in lung cancer cells and tissues, and GINS4 expression is not association with clinical risk factors, but linked with clinical stage and lymphatic metastasis status. Higher expression of GINS4 poorly linked with overall survival in lung adenocarcinomas. Furthermore, GINS4 promoted many characteristics of tumorigenesis including cell growth, clonal formation, migration and invasion, epithelial–mesenchymal transition, tumor sphere and tumor growth in vivo. Interestingly, our results demonstrated that LSH increases GINS4 expression through binding to 3’UTR region of GINS4 and stabilizing its mRNA levels. Finally, LSH overexpression rescues GINS4 knockdown-induced features. GINS4 facilitates lung cancer progression by promoting key characteristics of tumor potential, and LSH epigenetically interacts with and stabilizes GINS4 transcripts.